Resverlogix Corp.

Publications

Publications, Abstracts & Posters

ESC Congress - August 29, 2017: Apabetalone (RVX-208) Impacts Key Biomarkers and Pathways Associated with Cardiovascular Disease in Patients with Severe Renal Impairment

ESC Poster Link

ESC Congress - August 27, 2017: Lowering the Neutrophil to Lymphocyte Ratio by the BET Inhibitor, Apabetalone: Potential Implications for Cardiovascular Events in High Risk Patients

ESC Poster Link

American Diabetes Association Scientific Sessions 2017: Apabetalone (RVX-208) Lowers Major Adverse Cardiovascular Events (MACE) in Diabetes Mellitus by Affecting Complement Pathway and Microbiome Activity. Authors: Ewelina Kulikowski, Cyrus Calosing, Laura Tsujikawa, Sylwia Wasiak, Dean Gilham, Chris Halliday, Mike Sweeney, Jan Johansson, and Norman Wong

ADA Poster Link

Publication in Journal of Cardiovascular Translational Research: Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208). Authors: Sylwia Wasiak, Dean Gilham, Laura M. Tsujikawa, Christopher Halliday, Cyrus Calosing, Ravi Jahagirdar, Jan Johansson, Michael Sweeney, Norman C. Wong, Ewelina Kulikowski

Article Link

European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress 2017: Effects of Apabetalone (RVX-208) on Serum Albumin in Subjects with CVD, Diabetes and Chronic Kidney Disease; a Post-Hoc Analysis of the ASSURE and SUSTAIN Clinical Trials. Authors: Ewelina Kulikowski, Christopher Halliday, Ken Lebioda, Jan Johansson, Michael Sweeney and Kamyar Kalantar-Zadeh.

ERA-EDTA Poster Link 1

ERA-EDTA Congress 2017: Apabetalone, A Bromodomain and Extraterminal Protein Inhibitor, Decreases Key Factors in Vascular Calcification in Vitro and in Clinical Trials. Authors: Ewelina Kulikowski, Dean Gilham, Laura Tsujikawa, Sylwia Wasiak, Christopher Halliday, Brooke Rakai, Kamyar Kalantar-Zadeh, Ravi Jahagirdar, Mike Sweeney, Jan Johansson, Norman C.W. Wong, Richard Robson.

ERA-EDTA Poster Link 2

ATVB 2017: Apabetalone (RVX-208), a Selective BET Protein Inhibitor, Reduces Expression of Acute Phase Response Markers In Vitro and in Patients with Cardiovascular Disease and Chronic Kidney Disease

ATVB 2017 Poster Link

The 13th International Conference on Alzheimer's & Parkinson's Diseases 2017: Apabetalone, a BET Bromodomain Inhibitor, Suppresses Inflammatory Mediators in Microglia that Contribute to Neurodegenerative Disease. Authors: Ewelina Kulikowski, Dean Gilham, Laura Tsujikawa, Sylwia Wasiak, Christopher Halliday, Rowan Lind, Cyrus Calosing, Brooke Rakai, Jan O. Johansson, Michael Sweeney, Ravi Jahagirdar and Norman C.W. Wong.

AD/PD 2017 Poster Link

ACC 2017: Apabetalone (RVX-208) Lowers Cardiovascular Disease (CVD) In Diabetes Mellitus by a Mechanism Involving Microbiome Mediated Activity on the Complement Pathway. Authors: Ewelina Kulikowski, Cyrus Calosing, Laura Tsujikawa, Sylwia Wasiak, Dean Gilham, Christopher Halliday, Michael Sweeney, Jan Johansson, and Norman Wong.

ACC 2017 Poster Link

ASN 2016: Apabetalone Reduces Levels of Key Markers Involved in Vascular Calcification. Authors: Ewelina Kulikowski, Dean Gilham, Laura Tsujikawa, Sylwia Wasiak, Kamyar Kalantar-Zadeh, Christopher Halliday, Jan Johansson, Michael Sweeney, and Norman Wong.

ASN 2016 Poster Link

AHA 2016: Apabetalone (RVX-208) Reduces Expression of Acute Phase Response Markers in Vitro and in Patients with Cardiovascular Disease. Authors: Ewelina Kulikowski, Sylwia Wasiak, Dean Gilham, Cyrus Calosing, Laura Tsujikawa, Christopher Halliday, Michael Sweeney, Jan Johansson, and Norman C. W. Wong

AHA 2016 Poster Link

ESC Congress - August 28, 2016: Modulation of the complement cascade in cardiovascular disease patients by a bromodomain and extraterminal (BET) protein inhibitor

ESC Poster Link

AHA 2015: RVX-208 a Selective Bromodomain and Extra-Terminal BET Protein Inhibitor Acts on Several Pathways to Benefit Cardiovascular Risks. Authors: Ewelina Kulikowski, Sylwia Wasiak, Dean Gilham, Christopher Halliday, Kenneth Lebioda, Michael Sweeney, Jan Johansson, Norman Wong.

Link: http://circ.ahajournals.org/content/132/Suppl_3/A17127.abstract?sid=985beb63-a69e-4477-aaa1-25123ff48862 (abstract 17127)

ASN 2015: Alkaline Phosphatase Lowering by Selective BET Inhibition, a Novel Mechanism for MACE Reduction in High Risk CVD, Diabetes and CKD Patients; a Post-hoc Analysis of Phase 2b Studies with RVX-208. Authors: Kamyar Kalantar-Zadeh, Jan Johansson, Michael Sweeney, Ken Lebioda, Ewelina Kulikowski,  Christopher Halliday, Norman Wong.

Link: https://www.asn-online.org/abstracts/ (abstract TH-PO609)

RVX-208, Apabetalone, a First-in-Class Epigenetic BET Inhibitor, on ALP and eGFR in Subjects with CVD and CKD; a Post-hoc Analysis of ASSERT, SUSTAIN and ASSURE Clinical Trials. Authors: Kamyar Kalantar-Zadeh, Jan Johansson, Michael Sweeney, Ken Lebioda, Ewelina Kulikowski, Christopher Halliday, Norman Wong.

Link: https://www.asn-online.org/abstracts/ (abstract TH-PO666)

ACCRVX-208 the first selective bromodomain extra-terminal protein inhibitor being developed for patients with high residual risks of cardiovascular disease. Authors: Norman CW Wong; Jan Johansson; Kenneth Lebioda; Christopher Halliday; Ewelina Kulikowski. Link: http://content.onlinejacc.org/article.aspx?articleid=2197900

ATVBEffects of RVX-208 a Selective Bromodomain Extra-Terminal Protein Inhibitor Beyond Raising ApoA-I/HDL. Authors: Ewelina Kulikowski, Sylwia Wasiak, Sarah Attwell, Christopher Halliday, Dean Gilham, Laura Tsujikawa, Ravi Jahagirdar, Kenneth Lebioda, Jan Johansson, Mike Sweeney. Link: http://atvb.ahajournals.org/content/35/Suppl_1/A338.abstract?sid=a20e22bc-a1e3-4f49-88b1-c2d77f6a3afc

EASRVX-208 a selective bromodomain Extra-Terminal protein inhibitor reduces MACE in patients with high residual risks of cardiovascular disease, a post-hoc analysis. Authors: N.C.W. Wong, J.O. Johansson, K. Lebioda, C. Halliday, E. Kulikowski. Link: http://www.atherosclerosis-journal.com/article/S0021-9150(15)00263-4/abstract

ADAEffects of the ApoA-I Inducer RVX-208 on Glucose Metabolism in Individuals with Prediabetes. Authors: Andrew L. Siebel, Melissa F. Formosa, Alaina K. Natoli, Medini Reddy-Luthmoodoo, Andrew L. Carey, Gerrit Van Hall, Jim D. Otvos, Kerry-Anne Rye, Jan Johansson, Allan Gordon, Norman Wong, Philip Barter, Stephen J. Duffy, Bronwyn A. Kingwell. Link: http://www.abstractsonline.com/pp8/#!/3699/presentation/10373

EASDRVX-208 acts via an epigenetic mechanism to lower Major Adverse Cardiovascular Events (MACE) in patients with atherosclerosis and especially in those with diabetes mellitus. Authors: N.C.W. Wong, E. Kulikowski, L. Tsujikawa, D. Gilham, S. Wasiak, C. Halliday, K. Lebioda, J.O. Johansson, M. Sweeney. Link: http://www.easdvirtualmeeting.org/resources/rvx-208-acts-via-an-epigenetic-mechanism-to-lower-major-adverse-cardiovascular-events-mace-in-patients-with-atherosclerosis-and-especially-in-those-with-diabetes-mellitus--2

ISARVX-208 a selective bromodomain extra-terminal protein inhibitor Reduces MACE in Patients with high Residual Risks of Cardiovascular Disease. Authors: N.C.W. Wong, J.O. Johansson, K. Lebioda, E. Kulikowski, C. Halliday. Link: http://www.eventure-online.com/eventure/public/publicAbstractView.form?id=256145&congressId=8753

ESCEffects of RVX-208 on major adverse cardiac events (MACE), apolipoprotein A-I and High Density Lipoproteins; A post-hoc analysis from the pooled SUSTAIN and ASSURE clinical trials. Authors: J.A.N.O. Johansson, A.F. Gordon, C. Halliday, N.C. Wong. Link: http://spo.escardio.org/abstract-book/presentation.aspx?id=127290